Paladino BMA, Gualdo R, Scheffelaar KSA

Language: Spanish
References: 24
Page: 38-48
PDF size: 140.39 Kb.

Text Extraction

No abstract

REFERENCES

1. Akhtar S, Barash P. Significance of beta blockers in the perioperative period. Current opinion in Anaesthesiology 2002: 15;27- 35.

2. Sabbah HN. The cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol 1999, 22: 16-20.

3. Sheppard S et al. A bolus dose of esmolol attenuates tachycardia and hypertension after tracheal intubation. Can J anaesth,1990; 39:202-05.

4. Tobias J et al. Pulmonary reactivity to methacoline during betaadrenergic blockade: propanolol vs esmolol. Anaesthesiology, 1990;73:132-36.

5. De Nicola & MJ Sucre, Esmolol: en De Nicola A, Sucre MJ. Il Desflurane nelle specialità chirurgiche in: Desflurane nella moderna anestesia. Mosby Italia, Milano 2000 pag. 56 - 74.

6. Fita G et al. Esmolol in anesthesiology: pharmacology and indications. Rev Esp Anestesiol Reanim 1999;34: 404-14.

7. Stoschitzky J, Koshucharova G, Lercher P, Maier R,Sakotnik A, Klein W, Liebmann PM, Lindner W. Stereoselective effects of (R) - and (S) - carvedilol in humans. Chirality 2001, 13: 342-6.

8. Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 2001, 19: 152-71.

9. Eichhorn EJ. Experience with beta blockers in heart failure mortality trials. Clin Cardiol 1999, 22: 21-29

10. Van Bortel LM et al. Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol 1997; 51;379-84.

11. Lowes BD, Minobe W, Abraham WT, et al. Changes in gene expression in the intact human heart. Down regulation of alphamyosin heavy chain in hypertrophied, failing myocardium. J Clin Invest.1997; 100: 2315-2324.

12. Geenem DL, Malhotra A, Schever J, et al. Repeated cathecolamine surges after cardiac isomyosin expression but not protein synthesis in the rat heart. J Mol Cell Cardiol. 1997; 29: 2711-2716.

13. Bristow MR, Ginsburg R, Minobe W, et al. Decreased cathecolamine sensitivity and beta adrenergic receptor density in failing human hearts. N Engl J Med. 1982: 307: 205-211.

14. Unvarferth DV, Leier CV, Magorien RD, et al. Improvement of human myocardial mitochondria after dobutamine: A quantitative ultrastructural study. J Pharmacol Exp Ther. 1980; 215: 527-532.

15. Adamopoulos S, Pieoli M, Qiang F, et al. Effects of pulsed b stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet. 1995; 345: 344-349.

16. Braunwald E, Bristow M R. Congestive heart failure: fifty years of progress. Circulation 2000; 102:14-23.

17. Bristow M R. Beta adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101:558-569.

18. Stoschitzky J, Koshucharova G, Lercher P, Maier R,Sakotnik A, Klein W, Liebmann PM, Lindner W. Stereoselective effects of (R) - and (S) - carvedilol in humans. Chirality 2001, 13: 342-6.

19. Sweberg K. Bloqueo adrenérgico en la insuficiencia cardiaca: de las primeras esperanzas al estudio COPERNICUS. Revista del 27° congreso argentino de cardiología 2000; 12-15.

20. Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 2001, 19: 152-71.

21. Di Lenarda A, Sabbadini G, Sínagra G. Benefits of beta-blockers in heart failure: a class specific effect? Ital Heart J 2001, 2: 326-32.

22. Hjalmarson A. Prevention of sudden cardiac death with beta blockers. Clin Cardiol 1999, 22: 11-15.

23. Makris R.And Coriat P. Interactions Between Cardiovascular Treatments And Anaesthesia Currents Opinions In Anesthesiology 2001; 14:33-39.

24. Tavazzi L. Recomendación practica para el tratamiento beta bloqueante en la insuficiencia cardiaca, una propuesta de la asociación italiana de cardiólogos de hospital. Revista del colegio argentino de cardiología 1999; 3:19-20.